Sana Biotechnology Toekomstige groei

Future criteriumcontroles 0/6

De winst van Sana Biotechnology zal naar verwachting dalen met 3.8% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 83.6% per jaar. De winst per aandeel zal naar verwachting groeien met 6.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -69.1% zijn.

Belangrijke informatie

-3.8%

Groei van de winst

6.2%

Groei van de winst per aandeel

Biotechs winstgroei	26.9%
Inkomstengroei	83.6%
Toekomstig rendement op eigen vermogen	-69.1%
Dekking van analisten	Low
Laatst bijgewerkt	21 Oct 2024

Recente toekomstige groei-updates

Recent updates

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16

Winst- en omzetgroeiprognoses

NasdaqGS:SANA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-334	-267	-188	4
12/31/2025	N/A	-289	-244	-183	4
12/31/2024	N/A	-277	-168	-199	4
6/30/2024	N/A	-245	-285	-240	N/A
3/31/2024	N/A	-309	-274	-240	N/A
12/31/2023	N/A	-283	-274	-254	N/A
9/30/2023	N/A	-276	-288	-278	N/A
6/30/2023	N/A	-362	-292	-279	N/A
3/31/2023	N/A	-320	-307	-292	N/A
12/31/2022	N/A	-269	-311	-290	N/A
9/30/2022	N/A	-300	-346	-324	N/A
6/30/2022	N/A	-298	-335	-310	N/A
3/31/2022	N/A	-207	-310	-279	N/A
12/31/2021	N/A	-356	-281	-251	N/A
9/30/2021	N/A	-358	-212	-179	N/A
6/30/2021	N/A	-327	-198	-166	N/A
3/31/2021	N/A	-433	-183	-158	N/A
12/31/2020	N/A	-285	-162	-138	N/A
9/30/2020	N/A	-215	-155	-134	N/A
12/31/2019	N/A	-131	-112	-86	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat SANA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat SANA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat SANA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat SANA volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat SANA volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat SANA binnen 3 jaar verliesgevend zal zijn.

Sana Biotechnology Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 9.3% to US$12.20

Price target increased by 17% to US$10.50

Price target increased by 8.6% to US$9.50

Price target decreased by 10% to US$8.75

Price target decreased to US$9.75

Price target decreased to US$11.75

Recent updates

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

New minor risk - Financial position

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index

Price target increased by 9.3% to US$12.20

New major risk - Revenue and earnings growth

Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Sana Biotechnology: Now In Overbought Territory

Independent Director recently sold US$236k worth of stock

Price target increased by 17% to US$10.50

Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262

Insufficient new directors

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Executive VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting

Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Price target increased by 8.6% to US$9.50

New major risk - Revenue and earnings growth

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Price target decreased by 10% to US$8.75

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Price target decreased to US$9.75

High number of new directors

Price target decreased to US$11.75

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

High number of new directors

Sana Biotechnology A Buy For Potential Cancer Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2500 Growth Index

Sana Biotechnology, Inc. Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Sana Biotechnology, Inc. Plan to Relocate Manufacturing to Bothell

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington

Price target decreased to US$12.50

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology, Inc. to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Price target decreased to US$18.00

High number of new directors

Independent Director recently bought US$204k worth of stock

Price target decreased to US$23.67

Sana Biotechnology: Exciting Preclinical Science

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Executive VP notifies of intention to sell stock

Independent Director Geoffrey von Maltzahn has left the company

Senior VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology: Hypoimmune Cell Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 1000 Value Index

Sana Biotechnology reports Q1 results

Sana Biotechnology to Present Pre-Clinical Data At American Society of Gene & Cell Therapy Annual Meeting 2021

Sana Biotechnology, Inc. has completed an IPO in the amount of $587.5 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven